Buffer for a human joint and method of arthroscopically inserting

Abstract
A buffer (10) for placement in a human knee between the femur and tibia comprises an outer sack (14) formed of a pliable material and having a one-way valve (22), a generally circularly shaped inner ring (16) received within the outer sack (14), and a friction reducing fluid (18) received within the outer sack (14) via the one-way valve (22). The inner ring (16) includes top and bottom surfaces (38,40) angled inwardly with respect to each other, such that the ring (16) is generally concave. The buffer (10) is configured for insertion between the femur and tibia so as to at least partially prevent the bones from contacting each other, which reduces the pain and discomfort associated with a loss of articular cartilage (12). The buffer (10) is arthroscopically inserted in the knee using an especially designed sleeve (20) configured for support of the buffer (10) during insertion.
Description
BACKGROUND

1. Field


Embodiments of the present invention relate to apparatus and methods of providing a buffer for a human joint so as to prevent painful bone on bone contact. More particularly, embodiments of the present invention present a buffer for insertion between the femur and tibia in the human knee, so as to protect worn or damaged articular cartilage or exposed bone and to allow the articular surfaces remaining on the femur and tibia to continue to move against each other less painfully.


2. Description of the Related Art


The human knee joint is one of the most complex joints of the body and is also highly susceptible to damage because it is a weight bearing joint. The knee joint itself is comprised of the femur (thigh bone), the tibia (shin bone), the patella (kneecap), articular cartilage, and menisci, which are a type of crescent-shaped cartilage that lies between the femur and tibia. The menisci are located in the medial and lateral articulations of the knee and sometimes act as shock-absorbing pads. The knee is also compromised of tissues that are muscle, ligament, the lining tissue (synovium), and the synovial fluid which is secreted by the synovium.


The ends of the femur and tibia are coated with articular cartilage, which is smooth and hard, so as to provide the femur, tibia, and patella with a slick surface during normal movement. The articular cartilage has a very low coefficient of friction and can also receive large compressive loads, which makes it vital to ensure ease of movement of the knee joint and prevent bone on bone contact between the femur and tibia. Normal articular cartilage is about 50 times slicker than ice.


Over time, the articular cartilage on the femur and tibia, and in any other human joint, wears and degenerates, such that it thins or in some joints is completely lost. Upon wear of the articular cartilage, the slick, low friction surfaces from the cartilage are lost, and the ends of the femur and tibia banes are exposed. Without any protecting articular cartilage, the femur and tibia contact each. This bone on bone contact is painful, and is often the end result of osteoarthritis. Additionally, bones can also become hard and sclerotic over time with associated loss of articular cartilage, which can further increases the pain.


Many methods have been developed to either replace worn cartilage or otherwise minimize the pain associated with the loss of the articular cartilage. The methods have all had varying degrees of success but are often accompanied by very extensive and invasive surgery. All invasive methods are costly, often requiring implanting nonbiologic parts within the knee, or, in some instances, human cadaver parts. These methods of treatment also require lengthy rehabilitation, which often times leaves the patient in considerable pain.


One method of treatment that has been used is implantation of cadaver menisci. This method has had only limited success and multiple failures. A second method is chondroplasty, or removal of and thinning out the existing damaged cartilage. This method is used to smooth the cartilage to reduce the friction between the femur and tibia, and remove the flaps of cartilage that have delaminated from the bone. The success of this procedure is limited by the amount of cartilage remaining, and doctors guard against removal of too much of the articular cartilage so as to prevent exposure of the subchondral bone. For older patients or patients with traumatic arthritis of their knees, chondroplasty has only limited application because of the lack of healthy articular cartilage.


If the articular cartilage loss is small, an osteochondral autograft transplant (known as an OATS procedure) can be performed. The OATS procedure requires removing a dowel shaped portion of bone and replacing it with a commensurate dowel shaped portion of articular cartilage from another area of the knee, another joint, or even a cadaver. The OATS procedure is relatively invasive, has a fairly lengthy rehabilitation time, and has also only had limited success.


An even further alternative to repairing articular cartilage damage is growing the patient's own cartilage in tissue cultures and placing the newly grown cartilage in the areas of cartilage loss. This is an expensive and often unsuccessful method of treatment.


In the most extreme of cases of arthritis, the knee joint may be artificially resurfaced or even replaced. In artificial joint replacement, the ends of the femur and tibia are capped with plastic or metal pieces that are cemented to the ends of the bone. Alternatively, the ends of the femur and tibia can be replaced with a biologic ingrowth coating of the metal used, which removes the need for the cement. This procedure is presently the standard approach to treating severe osteoarthritis of the knee; however, the risks from this procedure are numerous, and this is particularly unfortunate for patients who can ill afford a major complication from this extensive surgery. In places where these artificial joints have been inserted, wear eventually occurs in the polyethylene surface between the metal caps, which can lead to bone destruction just from the particles of the polyethylene. Moreover, this procedure is not only quite invasive but requires a lengthy rehabilitation time. Thus, for these reasons, many doctors delay as long as possible this invasive procedure in many patients.


An even further method of treatment is arthrosporic debridement, which is much less invasive but almost always unsuccessful in limiting the pain from the damaged joint surface, unless most of the pain is from a torn cartilage or loose body in the joint that can be removed arthroscopically.


The problems associated with each of the above procedures are highly dependant on the age and medical condition of the patient. For older patients, their ability and desire to engage in an invasive procedure that requires lengthy rehabilitation is often limited. Moreover, for older patients who are not necessarily engaging in many activities or who do not require a long-term solution to adjust their pain and discomfort, having an invasive, complicated procedure performed is not ideal.


Accordingly, there is a need for a less risky and improved apparatus and method for alleviating and addressing pain resulting from a loss of articular cartilage. There is a need for a new apparatus and method of treatment of lost cartilage that extends beyond attempting to fix or replace damaged cartilage, but instead provides an apparatus and method of treatment that is minimally invasive, relatively inexpensive, requires relatively short rehabilitation time, and is suitable for older patients. This invention solves many of the above-described problems and provides a distinct advantage in the art of medical treatment for prevention of bone on bone contact due to the loss of articular cartilage. More particularly this invention provides a new apparatus and method of treatment to address the pain and discomfort associated with the loss of articular cartilage by interposing a thin but slick barrier between the tibia and femur. This invention provides a buffer between the femur and tibia in the human knee that does not require suturing or other permanent securement to muscles, ligaments, or tendons in the knee.


SUMMARY

The present invention solves the above-described problems and provides a distinct advance in the art of medical treatments for prevention of bone-on-bone contact due to the loss of articular cartilage. More particularly, the present invention provides a new method of treatment to address the pain and discomfort associated with the loss of articular cartilage. In particular, embodiments of the present invention provide a buffer independently held between a human's femur and tibia and that does not require suturing or other permanent securement to any muscle, ligament, or tendon in the knee.


The buffer of embodiments of the present invention comprises an outer sack formed of a pliable material and having a one-way valve; a generally circularly-shaped, rigid inner ring within the outer sack, the inner ring having a top surface and a bottom surface angled inwardly with respect to each other, such that the ring is generally concave; and a friction reducing fluid received within the outer sack via the one-way valve.


The buffer is inserted into the knee joint using a specially designed sleeve comprising a body and a stylus or plunger. The body is generally an ovoid hollow tube into which is inserted the buffer. The stylus or plunger includes a fluid line comprising a tube through which a fluid can be pumped. The fluid line and buffer, when received within the sleeve, are in fluid communication, such that the fluid can be inserted into the outer sack of the buffer once the buffer is positioned in the knee joint.


To insert the buffer into the sleeve, the buffer is compressed into the sleeve, and the stylus is screwed or otherwise secured to the rigid inner ring of the buffer. The stylus is then unscrewed from the buffer once the device is positioned in the knee joint and after the fluid is placed into the buffer via a one way valve in the buffer.


A method of inserting the buffer into the knee comprises the steps of providing the buffer, providing a sleeve having a stylus operable to securely receive the buffer during insertion, and injecting fluid into the outer sack during insertion via the one way valve located in the buffer. To insert the buffer in the sleeve, the buffer is compressed side to side, placed into the sleeve, and removably secured to the stylus. After being placed into the knee, the buffer is then injected with fluid to help the surfaces of the buffer move over each other by reducing friction between them. Once the buffer is injected with this fluid, the stylus is unscrewed form the rigid inner ring, the fluid is held in place by the one way valve, the sleeve is removed, the skin is closed, and the operation is complete.





BRIEF DESCRIPTION OF THE DRAWINGS

Embodiments of the present invention are described in detail below with reference to the attached drawing figures, wherein:



FIG. 1 is a perspective view of a human knee showing the skin removed and illustrating the femur, tibia, articular cartilage covering ends of the femur and tibia, and menisci;



FIG. 2 is a perspective view of a buffer of the present invention comprising an outer sack and an inner ring;



FIG. 3 is a perspective view of the inner ring of the buffer of the present invention; and



FIG. 4 is a perspective view of the buffer of the present invention received within a sleeve designed for arthroscopically inserting the buffer into a patient's knee.





The drawing figures do not limit the present invention to the specific embodiments disclosed and described herein. The drawings are not necessarily to scale, emphasis instead being placed upon clearly illustrating the principles of the invention.


DETAILED DESCRIPTION

Turning now to the drawing figures, and particularly FIG. 1, a buffer 10 for a human joint constructed in accordance with embodiments of the invention is illustrated. The buffer 10 is configured to be inserted into any human joint that is a bearing surface, such as the glenohumeral joint (shoulder joint) or the knee joint. Embodiments of the present invention will be discussed with respect to the knee joint, although it is to be understood that the invention is equally applicable to other joints.


The buffer 10 is configured to be inserted into a patient's knee in the space between the patient's femur and tibia and is intended to supplement any remaining articular cartilage 12 in the joint, or, in the instances where there is no remaining articular cartilage 12, provide a complete buffer between the femur and tibia. The buffer 10 is further sized so that it does not interfere with the menisci of the patient's knee, as illustrated in FIG. 1.


The buffer 10 of an embodiment of the present invention comprises an outer sack 14 enclosing an inner ring 16 and further configured to receive a friction reducing fluid 18, as illustrated in FIGS. 1 and 2. As described in more detail below, the buffer 10 may be arthroscopically inserted into the patient's knee using a sleeve 20, illustrated in FIG. 4, especially designed for stable securement of the buffer 10 during the arthroscopic procedure.


The outer sack 14 of the buffer 10 is generally circular in shape, although the sack 14 may also be generally oval in shape while being inserted into the knee through the sleeve 20. The sack 14 is preferably approximately 10-50 mm in size, and more preferably approximately 30-60 mm, and most preferably approximately 35-45 mm. In an average patient, the space between the femur and tibia with an average amount of articular cartilage can be opened to 10-15 mm at arthroscopy but contract to 0 mm when the stress on the ligament is relaxed. The sack 14 having the inner ring 16 located therein has a height that is preferably at least the distance between the femur and tibia, i.e., approximately 10 mm, and is flexible. More preferably, the sack's height is slightly larger than the distance between the femur and tibia, such that the height of the sack 14 is approximately the same height as the inner ring. In embodiments of the invention, the buffer, including the inner ring, are manufactured in various sizes to accommodate differently-sized knee joints.


The sack 14 is preferably formed of a material that will be accepted by a human body and that is durable. Because of the pressure that the sack 14 will receive due to the contraction and movement of the femur and tibia, the sack 14 is further preferably formed of a pliable, resilient material. The material is also impermeable, such that the friction reducing fluid 18 does not escape from the sack 14. An exemplary material includes polyethylene, although any material having the above-described properties will suffice. The material forming the sack 14 may be translucent, as illustrated in FIG. 2, or opaque.


The sack 14 includes a one-way valve 22 that is fluidly connected to a hollow fluid line 24, as illustrated in FIGS. 1 and 2. The hollow fluid line 24 allows for passage of the fluid 18 therethrough. The friction reducing fluid 18, described in more detail below, is inserted into the sack 14 after the buffer 10 is positioned inside the patient's knee. The fluid 18 is inserted into the sack 14 via the fluid line 24, which will be of a length sufficiently long to allow insertion of the fluid 18 into the sack 14 via the sleeve 20 or other instrument, as also described in more detail below. The valve 22 preferably includes threads 23 (not shown) After the fluid 18 is inserted into the sack 14, the fluid line 24 is preferably unscrewed. Alternatively, the line 24 may be cut proximal to the sack 14 or otherwise formed so that it can be removed from the sack 14. The one-way valve 22 allows receipt of the friction reducing fluid 18 via the filler line 24 and after the buffer 10 is inserted into the patient's knee. The valve 22 is one-way, however, so that it does not allow for escape of the fluid 18 via the valve 22.


The friction reducing fluid 18 is any fluid that is accepted by a human body and that assists in allowing ease of movement of the inner ring 16 within the outer sack 14. Exemplary friction reducing fluids 18 include the patient's own synovial fluid found in synovial joints, such as the knee joint, and artificial fluids, such as SYNVISC®, manufactured by Genzyme Corporation.


The inner ring 16 is generally circular in shape, although the ring 16 may also be generally oval in shape. During insertion, the inner ring is flexed to be oval in shape. The inner ring 16 is preferably approximately 20-60 mm in circumference, and more preferably approximately 25-55 mm, and most preferably approximately 27.5-32.5 mm. The inner ring 16 is manufactured therefore to fit within the sack 14. In preferred form, the inner ring 16 and sack 14 are manufactured as a unit, such that the inner ring 16 is located within the sack 14 and sold as single unit. As noted above, the sack and inner ring may be manufactured in various sizes to fit each particular patient.


The inner ring 16 is preferably solid and formed of a resiliently rigid material, such that the ring 16 can withstand, with little or no deformation along a longitudinal axis A, a relatively high degree of loading pressure occurring from placement between the femur and tibia, yet can also be flexed or otherwise deformed along a transverse axis B for ease of placement within the patient's knee. In particular, during insertion in the knee joint, the ring 16 can be compressed side to side along axis B for placement in the sleeve. However, the ring's 16 resiliently rigid material allows it to return to its generally circular shape once the pressure along the axis B is removed and the buffer is placed between the tibia and femur.


The ring 16 preferably comprises an outer surface 26 having a top edge 28 and a bottom edge 30, an inner surface 32 having a top edge 34 and a bottom edge 36, a top surface 38, and a bottom surface 40. The outer, inner, top, and bottom surfaces 26,32,38,40 are preferably integrally formed and together define a hollow interior 42 of the ring 16. The top and bottom surfaces 38,40 are angled inwardly with respect to each other, such that the top surface 38 extends downwardly from the top edge 28 of the outer surface 26 and to the top edge 34 of the inner surface 32, and similarly, the bottom surface 40 extends upwardly (not shown) from the bottom edge 30 of the outer surface 26 and up to the bottom edge 36 of the inner surface 32. In this manner, the top and bottom surfaces 38,40 form the ring 16 that is generally concave when viewed from a top of the ring 16 and flat when viewed from a bottom of the ring 16. This further provides a ring wherein a height of the ring along an outer diameter is larger than a height of the ring along an inner diameter, as illustrated in FIG. 3.


The concavity of the ring 16 and the orientation of the top and bottom surfaces 38,40 forms a generally V-shaped cross-section of the ring 16 when cut along the longitudinal axis A. The concavity assists with placement and retention of the buffer 10 between the patient's femur and tibia in the patient's knee. In particular, the buffer 10 is partially held in place within the patient's knee and between the femur and tibia by the load-bearing pressure that naturally occurs from the muscles, ligaments, and bones in the patient's knee and the weight of the body. However, to insure that the buffer 10 does not drift outside its proper placement when the knee is not exhibiting load-bearing pressure, the concave top and bottom surfaces 38,40 of the inner ring 16 assist in locating the buffer 10 between the femur and tibia.


As illustrated in FIG. 4, the sleeve 20 used to insert the buffer 10 into the knee comprises a generally ovoid, hollow body 44, a stylus or telescoping plunger 46 (not necessarily drawn to scale with respect to length in FIG. 4) having proximal and distal ends 48,50 and at least partially housed within the body 44, and the fluid line 24 having proximal and distal ends 54,56, partially housed within the body 44 and 46, and operable to allow the passage of fluid therethrough. The body 44 of the sleeve 20 is generally ovoid to accommodate the shape of the buffer 10 upon insertion, as described in more detail below. The fluid line 24 is passed through the plunger 46 and is screwed onto and fluidly connected with the valve 22 of the sack 14 at the proximal end 54 of the line 24 and with a fluid source (not shown) at the distal end 56 of the line 24.


The plunger 46 includes a curved neck 58 located at the proximal end 48 and operable to support the buffer 10 during placement in the patient's knee. The buffer 10 is preferably flexed along the transverse axis B into a generally ovoid shape so as to be partially inserted into the hollow body 44 of the sleeve 20, as illustrated in FIG. 4. The buffer 10 is inserted into the body 44 such that the valve 22 of the buffer 10 is screwed into fluid communication with the fluid line 24. Additionally, during insertion the buffer is supported by the curved neck 58 of the plunger 46.


The buffer 10 is preferably arthroscopically inserted into the patient's knee using the sleeve 20. The buffer 10 is flexed into the generally ovoid shape illustrated in FIG. 1 and then positioned within the sleeve 20. Flexing the buffer 10 into the ovoid shape facilitates insertion into the knee joint. The buffer 10 is held into place during insertion by being supported by the neck 58. Alternatively, the neck 58 could include further structure (not shown) for supporting and holding the buffer 10 at least partially in the sleeve 20 during insertion, such as a U-shaped arm that receives the buffer 10.


As discussed briefly above and as illustrated in FIG. 1, the buffer 10 is inserted between the tibia and femur of the knee joint. The buffer 10 can be inserted on either side of the knee, as illustrated in FIG. 1.


As noted above, upon insertion, the buffer 10 is flexed into the ovoid shape. Once the buffer 10 is released from the sleeve 20, it springs back into its generally circular shape, as illustrated in FIG. 1. Once inserted, the friction reducing fluid 18 is then inserted into the buffer 10 via the fluid line 24, which is fluidly connected between the one way valve 22 of the buffer 10 and the sleeve 20. Alternatively, the fluid 18 may be inserted into the buffer 10 prior to placement between the femur and tibia and/or prior to release from the sleeve 20. As noted above, after the fluid is inserted into the sack 14, the fluid line 24 is preferably physically separated from the buffer, so as to not be an irritant to the patient, by either cutting the line 24 proximal to the sack 14 or otherwise forming the line 24 so that it can be removed from the sack 14.


Once inserted, the rigidity of the inner ring 16 of the buffer 10 acts to keep the femur and tibia separated, such that the two bones are not contacting each other. Additionally, as noted above, once inserted, the load-bearing pressure of the femur and tibia assist in locating and holding the buffer in place between the bones. The concavity of the top and bottom surfaces 38,40 of the ring 16 further assists in holding the buffer 10 in place, especially when there is no load-bearing pressure exhibited between the femur and tibia. The friction reducing fluid 18 then assists in movement of the femur and tibia against the buffer 10 and in particular, the inner ring 16 of the buffer 10.


The buffer 10 is advantageously independently held within the knee joint and does not have to be sutured to any muscle, ligament, or tendon. Moreover, the buffer 10 can be used with any amount of articular cartilage 12 and menisci, such that it is not limited to being only used with very little cartilage. Although the buffer of embodiments of the present invention are preferably permanent, it is to be understood that with time, the buffer 10 may become sufficiently worn so as to require replacement. However, such will likely not be the norm, and the buffer 10 is expected to last many years, depending on the activity level, weight, and age of the patient and other common degradation factors.


Although the invention has been described with reference to the preferred embodiment illustrated in the attached drawing figures, it is noted that equivalents may be employed and substitutions made herein without departing from the scope of the invention as recited in the claims. For example, the sleeve 20 could not include the fluid line 24, such that the friction reducing fluid 18 is inserted via a separate line and a syringe 62, as illustrated in FIG. 1.


Having thus described the preferred embodiment of the invention, what is claimed as new and desired to be protected by Letters Patent includes the following:

Claims
  • 1. An apparatus comprising: a pliable and resilient sack; anda reinforcement structure housed within the sack, the reinforcement structure having top and bottom surfaces with common inner and outer perimeters and being independently movable within and with respect to the sack, wherein at least one of the top and bottom surfaces of the reinforcement structure is angled with respect to the other surface, such that at least one of the top and bottom surfaces extends towards the other surface from the outer perimeter and to the inner perimeter,said apparatus configured for insertion between two bones of a human body so as to at least partially prevent the bones from contacting each other; and wherein the sack completely covers the top and/or the bottom surfaces of the reinforcement structure.
  • 2. The apparatus of claim 1, wherein the reinforcement structure is a generally circular or oval-shaped ring received within the sack.
  • 3. The apparatus of claim 1, wherein the inner perimeter of the reinforcement structure is an annular inner wall, and the outer perimeter of the reinforcement structure is an annular outer wall.
  • 4. The apparatus of claim 1, wherein the inner perimeter of the reinforcement structure defines a hollow interior.
  • 5. The apparatus of claim 1, wherein a fluid receiver is mounted on the sack.
  • 6. The apparatus of claim 5, wherein the receiver includes an engagement structure operable to securely mate with a fluid-delivery device.
  • 7. The apparatus of claim 6, wherein the engagement structure is an external thread.
  • 8. The apparatus of claim 5, wherein the receiver includes a one-way valve operable to receive and retain fluid within the sack.
  • 9. A buffer for placement between a human's femur and tibia, the buffer comprising: a pliable and resilient sack; anda ring housed within the sack, the ring having upper and lower surfaces, an outer diameter, and an inner diameter and being independently movable within and with respect to the sack, wherein the inner diameter is less than the outer diameter,wherein the ring is operable to (i) deform along a first axis that is generally parallel to the upper and lower surfaces when subjected to pressure, and (ii) substantially resist deformation along a second axis that is generally perpendicular to the first axis when subjected to pressure,wherein said buffer is configured for insertion between the femur and tibia so as to at least partially prevent the bones from contacting each other; and wherein the sack completely covers the upper and/or the lower surfaces of the ring.
  • 10. The buffer of claim 9, wherein the sack occupies a volume and includes a cavity configurable to be filled with a fluid, the sack being configurable to substantially conform to the ring to decrease the volume when the cavity is not filled with the fluid.
  • 11. The buffer of claim 9, further comprising: a regulator on the sack operable to permit upper and lower surfaces of the sack to be increasingly spaced from each other.
  • 12. The buffer of claim 11, wherein the regulator is a one-way valve for receipt of a friction reducing fluid into the sack to define a space between the upper and lower surfaces of the sack.
  • 13. A buffer for placement between a human's femur and tibia, the buffer comprising: a pliable and resilient sack;a ring housed within the sack, the ring having upper and lower surfaces, an outer diameter, and an inner diameter and being independently movable within and with respect to the sack; anda fluid receiver including an engagement structure operable to securely mate with a fluid-delivery device, the fluid receiver being mounted on the sack, wherein the inner diameter is less than the outer diameter,wherein the ring is operable to (i) deform along a first axis that is generally parallel to the upper and lower surfaces when subjected to pressure, and (ii) substantially resist deformation along a second axis that is generally perpendicular to the first axis when subjected to pressure,wherein said sack occupies a volume and includes a cavity configurable to be filled with a fluid, the sack being configurable to substantially conform to the ring to decrease the volume when the cavity is not filled with the fluid,wherein said buffer is configured for insertion between the femur and tibia so as to at least partially prevent the bones from contacting each other, andwherein the fluid receiver includes a one-way valve operable to receive and retain fluid within the sack.
RELATED APPLICATION

This patent application claims priority to and is a continuation of U.S. Pat. No. 7,976,578, issued Jul. 12, 2011, and entitled “Buffer for a Human Joint and Method of Arthroscopically Inserting,” which is hereby incorporated by reference in its entirety.

US Referenced Citations (177)
Number Name Date Kind
4166292 Bokros Sep 1979 A
4502161 Wall Mar 1985 A
4863477 Monson Sep 1989 A
4919667 Richmond Apr 1990 A
4919668 Rosenbaum et al. Apr 1990 A
4932969 Frey et al. Jun 1990 A
5344459 Swartz Sep 1994 A
5549679 Kuslich Aug 1996 A
5593445 Waits Jan 1997 A
5674296 Bryan et al. Oct 1997 A
5893889 Harrington Apr 1999 A
6022376 Assell et al. Feb 2000 A
6206927 Fell et al. Mar 2001 B1
6248131 Felt et al. Jun 2001 B1
6419704 Ferree Jul 2002 B1
6482234 Weber et al. Nov 2002 B1
6527804 Gauchet et al. Mar 2003 B1
6582466 Gauchet Jun 2003 B1
6629997 Mansmann Oct 2003 B2
6632235 Weikel et al. Oct 2003 B2
6679914 Gabbay Jan 2004 B1
6682562 Viart et al. Jan 2004 B2
6733532 Gauchet et al. May 2004 B1
6733533 Lozier May 2004 B1
6893465 Huang May 2005 B2
6984246 Huang Jan 2006 B2
7001431 Bao et al. Feb 2006 B2
7004971 Serhan et al. Feb 2006 B2
7244273 Pedersen et al. Jul 2007 B2
7250060 Trieu Jul 2007 B2
7297161 Fell Nov 2007 B2
7485145 Purcell Feb 2009 B2
7527647 Spence May 2009 B2
7534268 Hudgins et al. May 2009 B2
7618457 Hudgins Nov 2009 B2
7641691 Lotz et al. Jan 2010 B2
7645301 Hudgins et al. Jan 2010 B2
7708777 O'Neil et al. May 2010 B2
7744630 Lancial Jun 2010 B2
7799079 Hestad et al. Sep 2010 B2
7803193 Steinberg Sep 2010 B2
7819919 Fell Oct 2010 B2
7824444 Biscup et al. Nov 2010 B2
7837739 Ogilvie Nov 2010 B2
7842088 Rashbaum et al. Nov 2010 B2
7927374 Duggal et al. Apr 2011 B2
7976578 Marvel Jul 2011 B2
8034080 Malandain et al. Oct 2011 B2
8038698 Edidin et al. Oct 2011 B2
8057547 Hurlbert et al. Nov 2011 B2
8062375 Glerum et al. Nov 2011 B2
8100964 Spence Jan 2012 B2
8147517 Trieu et al. Apr 2012 B2
8147526 Auyoung Apr 2012 B2
8202320 Burgess et al. Jun 2012 B2
8206439 Gomez Duran Jun 2012 B2
8211175 Eisermann et al. Jul 2012 B2
8277508 Trieu Oct 2012 B2
8292955 Robinson et al. Oct 2012 B2
8435301 Gerber et al. May 2013 B2
8506633 Trieu Aug 2013 B2
8551172 Park Oct 2013 B2
8636803 Hibri et al. Jan 2014 B2
20020029080 Mortier et al. Mar 2002 A1
20020045942 Ham Apr 2002 A1
20020049498 Yuksel et al. Apr 2002 A1
20020147496 Belef et al. Oct 2002 A1
20020183848 Ray et al. Dec 2002 A1
20030009224 Kuras Jan 2003 A1
20030045939 Casutt Mar 2003 A1
20030191534 Viart et al. Oct 2003 A1
20030195628 Bao et al. Oct 2003 A1
20030199982 Bryan Oct 2003 A1
20040059416 Murray et al. Mar 2004 A1
20040088047 Spence et al. May 2004 A1
20040093082 Ferree May 2004 A1
20040127982 Machold et al. Jul 2004 A1
20040148026 Bonutti Jul 2004 A1
20040236425 Huang Nov 2004 A1
20040243238 Arnin et al. Dec 2004 A1
20040249462 Huang Dec 2004 A1
20040260396 Ferree et al. Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050010297 Watson et al. Jan 2005 A1
20050015150 Lee Jan 2005 A1
20050027307 Schwartz et al. Feb 2005 A1
20050033432 Gordon et al. Feb 2005 A1
20050038509 Ashe Feb 2005 A1
20050043804 Gordon et al. Feb 2005 A1
20050090901 Studer Apr 2005 A1
20050113923 Acker et al. May 2005 A1
20050197702 Coppes et al. Sep 2005 A1
20050197705 Arnin et al. Sep 2005 A1
20050251259 Suddaby Nov 2005 A1
20050267580 Suddaby Dec 2005 A1
20060129240 Lessar et al. Jun 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060241758 Peterman et al. Oct 2006 A1
20060241765 Burn et al. Oct 2006 A1
20060241766 Felton et al. Oct 2006 A1
20060241778 Ogilvie Oct 2006 A1
20060247780 Bert Nov 2006 A1
20060293750 Sherman et al. Dec 2006 A1
20060293751 Lotz et al. Dec 2006 A1
20070038300 Bao et al. Feb 2007 A1
20070038301 Hudgins Feb 2007 A1
20070050020 Spence Mar 2007 A1
20070050032 Gittings et al. Mar 2007 A1
20070073402 Vresilovic et al. Mar 2007 A1
20070135921 Park Jun 2007 A1
20070135922 Trieu Jun 2007 A1
20070148242 Vilei et al. Jun 2007 A1
20070150060 Trieu Jun 2007 A1
20070150061 Trieu Jun 2007 A1
20070162137 Kloss et al. Jul 2007 A1
20070168031 Hudgins et al. Jul 2007 A1
20070173940 Hestad et al. Jul 2007 A1
20070179607 Hodorek et al. Aug 2007 A1
20070179608 Ek et al. Aug 2007 A1
20070233258 Hestad et al. Oct 2007 A1
20070233259 Muhanna et al. Oct 2007 A1
20070260317 Ankney et al. Nov 2007 A1
20070293947 Mansmann Dec 2007 A1
20080033555 Link et al. Feb 2008 A1
20080051889 Hodorek Feb 2008 A1
20080065210 McKay Mar 2008 A1
20080065216 Hurlbert et al. Mar 2008 A1
20080086210 Fox Apr 2008 A1
20080103607 Krehl May 2008 A1
20080125860 Webler et al. May 2008 A1
20080125863 McKay May 2008 A1
20080132934 Reiley et al. Jun 2008 A1
20080133008 Truncale et al. Jun 2008 A1
20080234686 Beaurain et al. Sep 2008 A1
20090030399 Raiszadeh Jan 2009 A1
20090043389 Vunjak-Novakovic et al. Feb 2009 A1
20090043398 Yakimicki et al. Feb 2009 A1
20090069894 Duggal et al. Mar 2009 A1
20090088846 Myung et al. Apr 2009 A1
20090112323 Hestad et al. Apr 2009 A1
20090222081 Linder et al. Sep 2009 A1
20090222093 Liu et al. Sep 2009 A1
20090222098 Trieu et al. Sep 2009 A1
20090222099 Liu et al. Sep 2009 A1
20090222103 Fitz et al. Sep 2009 A1
20090248160 Suddaby Oct 2009 A1
20090259314 Linder-Ganz et al. Oct 2009 A1
20090264995 Subramanian Oct 2009 A1
20090306778 Marvel Dec 2009 A1
20100023126 Grotz Jan 2010 A1
20100070032 Park Mar 2010 A1
20100145454 Hoffman Jun 2010 A1
20100152855 Kuslich et al. Jun 2010 A1
20100262240 Chavatte et al. Oct 2010 A1
20100268341 Dvorak et al. Oct 2010 A1
20100280615 Baumgartner et al. Nov 2010 A1
20100292798 Maestretti Nov 2010 A1
20110098816 Jacob et al. Apr 2011 A1
20110144757 Linares Jun 2011 A1
20110172768 Cragg et al. Jul 2011 A1
20110224791 Hodorek et al. Sep 2011 A1
20110224801 Mansmann Sep 2011 A1
20110238180 Fritz et al. Sep 2011 A1
20110288642 Forsell Nov 2011 A1
20110319996 Barrall Dec 2011 A1
20120010713 O'Halloran et al. Jan 2012 A1
20120022649 Robinson et al. Jan 2012 A1
20120165941 Rabiner et al. Jun 2012 A1
20120179247 Navia Jul 2012 A1
20120265304 Mayer Oct 2012 A1
20120316645 Grotz Dec 2012 A1
20130123922 McCormack May 2013 A1
20130131806 Carpenter May 2013 A1
20130282121 Prewett Oct 2013 A1
20130289725 Donovan et al. Oct 2013 A1
20130297025 Wardlaw Nov 2013 A1
20140031926 Kudlik et al. Jan 2014 A1
Related Publications (1)
Number Date Country
20110270393 A1 Nov 2011 US
Continuations (1)
Number Date Country
Parent 12133211 Jun 2008 US
Child 13179869 US